ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Autor: Duygu Tosun, Jozef Hanes, Branislav Kovacech, Tomas Hromadka, Lutz Froelich, Stanislav Katina, Lubica Fialova, Michal Prcina, Norbert Zilka, Andrej Kovac, Reinhold Schmidt, Eva Kontsekova, Martin Rakusa, Martin Cente, Carmen Prenn-Gologranc, Milica G. Kramberger, Stanislav Sutovsky, Peter Koson, Markus Otto, Stefan Ropele, Petr Novak, John Harrison, Michal Novak, Roman Sivak, Juraj Piestansky, Matej Ondrus, Jaroslav Galba, Miroslav Smisek, Maria Samcova, Eva Stevens, Jakub Hort, Bengt Winblad, Philip Scheltens, Vojtech Parrak, Peter Filipcik, Michal Fresser, Natalia Paulenka-Ivanovova

Publikováno v: Nature Aging, 1(6), 521-534. Springer
Novak, P, Kovacech, B, Katina, S, Schmidt, R, Scheltens, P, Kontsekova, E, Ropele, S, Fialova, L, Kramberger, M, Paulenka-Ivanovova, N, Smisek, M, Hanes, J, Stevens, E, Kovac, A, Sutovsky, S, Parrak, V, Koson, P, Prcina, M, Galba, J, Cente, M, Hromadka, T, Filipcik, P, Piestansky, J, Samcova, M, Prenn-Gologranc, C, Sivak, R, Froelich, L, Fresser, M, Rakusa, M, Harrison, J, Hort, J, Otto, M, Tosun, D, Ondrus, M, Winblad, B, Novak, M & Zilka, N 2021, ' ADAMANT : a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease ', Nature Aging, vol. 1, no. 6, pp. 521-534 . https://doi.org/10.1038/s43587-021-00070-2

Alzheimer’s disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter placebo-controlled trial of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9207a075a751b59f0b0c380b710aaf1
https://research.vumc.nl/en/publications/61abe2cc-82ad-4ac3-93be-d1cbc548881b